Description of Medical Areas
About the FDA Approved Listings
|
 |
Drugs Approved by the FDA (2003)
|
The following drugs have been approved this year by
the Food and Drug Administration.
Cardiology/Vascular Diseases
|
|
Crestor (rosuvastatin calcium); For the treatment of primary hypercholesterolemia (heterozygous
familial and nonfamilial) and mixed dyslipidemia; AstraZeneca; Approved August 2003 Levitra (vardenafil); For the treatment of erectile dysfunction related to sexual activity in men; Bayer, GlaxoSmithKline; Approved September 2003
Dental/Maxillofacial Surgery
|
|
Dermatology/Plastic Surgery
|
|
Amevive (alefacept); For moderate to severe chronic plaque psoriasis.; Biogen; Approved January 2003
Aldurazyme (laronidase); For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65; Genzyme; Approved May 2003 Somavert (pegvisomant); Injectable formulation for the treatment of acromegaly; Pharmacia; Approved March 2003
Aloxi (palonosetron); For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; MGI Pharma, Helsinn Healthcare; Approved August 2003 Emend (aprepitant); For the treatment of nausea and vomiting associated with chemotherapy; Merck; Approved March 2003
Bexxar; For the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma following chemotherapy relapse; Corixa; Approved June 2003 Levitra (vardenafil); For the treatment of erectile dysfunction related to sexual activity in men; Bayer, GlaxoSmithKline; Approved September 2003 Reyataz (atazanavir sulfate); For the treatment of HIV-1 infection in combination with other antiretroviral agents; Bristol-Myers Squibb; Approved July 2003
Immunology/Infectious Diseases
|
|
Amevive (alefacept); For moderate to severe chronic plaque psoriasis.; Biogen; Approved January 2003 Fuzeon (enfuvirtide); For the treatment of HIV-1 infection in combination with other antiretroviral agents; Trimeris, Roche; Approved March 2003 Lexiva (fosamprenavir calcium); For the treatment of HIV infection in adults in combination with other antiretroviral agents.; GlaxoSmithKline; Approved October 2003 Reyataz (atazanavir sulfate); For the treatment of HIV-1 infection in combination with other antiretroviral agents; Bristol-Myers Squibb; Approved July 2003
Aldurazyme (laronidase); For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65; Genzyme; Approved May 2003 Boniva (ibandronate); For the treatment and prevention of osteoporosis; Roche / GlaxoSmithKline; Approved May, 2003 -- UPDATED: NEW FORMULATION APPROVED MARCH, 2005 Somavert (pegvisomant); Injectable formulation for the treatment of acromegaly; Pharmacia; Approved March 2003 Velcade (bortezomib); Injectable agent for the treatment of multiple myeloma patients who have received at least two prior therapies.; Millennium Pharmaceuticals; Approved May 2003
Cialis (tadalafil); Oral agent for the treatment for erectile dysfunction; Eli Lilly; Approved December 2003 Levitra (vardenafil); For the treatment of erectile dysfunction related to sexual activity in men; Bayer, GlaxoSmithKline; Approved September 2003 Namenda (memantine HCl); For the treatment of moderate to severe dementia of the Alzheimer’s type.; Forest Laboratories; Approved October 2003
Aloxi (palonosetron); For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; MGI Pharma, Helsinn Healthcare; Approved August 2003 Bexxar; For the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma following chemotherapy relapse; Corixa; Approved June 2003 Emend (aprepitant); For the treatment of nausea and vomiting associated with chemotherapy; Merck; Approved March 2003 Iressa (gefitinib); For the second-line treatment of non-small-cell lung cancer; AstraZeneca; Approved May 2003 Velcade (bortezomib); Injectable agent for the treatment of multiple myeloma patients who have received at least two prior therapies.; Millennium Pharmaceuticals; Approved May 2003
Aldurazyme (laronidase); For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65; Genzyme; Approved May 2003
Pulmonary/Respiratory Diseases
|
|
Aldurazyme (laronidase); For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65; Genzyme; Approved May 2003 Iressa (gefitinib); For the second-line treatment of non-small-cell lung cancer; AstraZeneca; Approved May 2003
Trauma/Emergency Medicine
|
|
|
|
Back to Centerwatch Drug Directories
|
